Company
Curium
Paris-based radiopharmaceutical maker formed in 2017 from IBA Molecular and Mallinckrodt Nuclear Medicine. US base in St. Louis.
1 story
Regulatory News has published 1 story about Curium on 22 September 2026, sourced to the primary record — the regulator’s decision, the company’s filing or its own announcement. This page is generated from that coverage. Last updated 22 September 2026.
This page is generated from Regulatory News’ editorial coverage of Curium. It is not an advertisement.
On the record
- Company
- Curium (Curium US LLC / Curium Group)
- Headquarters
- Paris, France; U.S. operations headquartered in St. Louis, Missouri
- Founded
- April 2017, formed by the merger of IBA Molecular and Mallinckrodt Nuclear Medicine
- Regulator
- U.S. Food and Drug Administration (CDER), via the 505(b)(2) pathway
- Latest milestone
- FDA approval of BEXLUTRY, the first radioligand equivalent
Each line is taken from the most recent story of ours that states it.
Products in our coverage
Our coverage
